Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 5/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30128868 | 1.00 | IDO1 (0.65) | IDO1LMNAMEN1ALDH1A1GAA | |
| SCHEMBL24878193 | 0.89 | IDO1 (0.51) | IDO1LMNAMEN1ALDH1A1GAA | |
| SCHEMBL30128989 | 0.87 | IDO1 (0.81) | IDO1LMNAMEN1ALDH1A1GAA | |
| SCHEMBL24878335 | 0.87 | IDO1 (0.81) | IDO1LMNAMEN1ALDH1A1GAA | |
| SCHEMBL31011175 | 0.87 | IDO1 (0.81) | IDO1LMNAMEN1ALDH1A1GAA | |
| SCHEMBL24878331 | 0.87 | IDO1 (0.81) | IDO1LMNAMEN1ALDH1A1GAA | |
| SCHEMBL24878110 | 0.87 | IDO1 (0.81) | IDO1LMNAMEN1ALDH1A1GAA | |
| SCHEMBL24878741 | 0.87 | IDO1 (0.81) | IDO1LMNAMEN1ALDH1A1GAA | |
| SCHEMBL24878101 | 0.86 | IDO1 (0.60) | IDO1LMNAMEN1ALDH1A1GAA | |
| SCHEMBL30129258 | 0.86 | IDO1 (0.60) | IDO1LMNAMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | IDO1 1/4885LMNA 4773/4885MEN1 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.